NRXS · Neuraxis Inc
United States · RS rating 61 · As of 2026-11-03
| Price | 6.58 USD |
|---|---|
| 1-day change | -0.3% |
| RS rating (overall / 1M / 3M / 12M) | 61 / 39 / 60 / 96 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 33 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -5.6% |
| Sales growth Q/Q | +19.3% |
| Distance from 52-week high | +25.3% |
| Market cap (USD) | $85.7M |